Released May 5, 2026, before the open
10-Q filed May 5, 2026, 35 days after period end · 0001171843-26-003006
Q1 2026 · 10-Q
Revenue—
Net Income-$18.32M-$18.32M N/M vs Q1 2025N/M vs Q4 2025
EPS, diluted—
Operating Income-$20,299,000N/M
Operating Cash Flow-$17,269,000N/M
Free Cash Flowderived-$17,351,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$18.32M | -$16.63M | -$10.79M | -$7.84M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR